T he HIV-1 epidemic continues to spread worldwide, and an effective vaccine to prevent infection remains elusive. A major barrier to HIV vaccine development is a limited understanding of the key components of protective immunity against HIV infection. To define these components, considerable attention has been given to the minority of HIV-1-infected individuals who control viral replication and remain asymptomatic for 10 years or more (1-3), so-called "long-term nonprogressors" (LTNPs), 3 who account for no more than 2-5% of HIV-1-infected cohorts. Fewer studies have addressed the relationship between the immune response and control of viral replication with clinical outcome in HIV-2 infection. The clinical course of HIV-2 infection is distinct from that of HIV-1. Despite a close phylogenetic relationship between the viruses, mortality rates are substantially lower in HIV-2-than in HIV-1-infected populations (4, 5) . Although many HIV-2-infected individuals experience nonprogressive disease (4), a minority develop higher levels of plasma viral load and CD4 ϩ T cell decline (6) , leading to an immunodeficiency syndrome indistinguishable from AIDS caused by HIV-1. Thus, most HIV-2-infected individuals behave as LTNPs although in a minority of cases the virus is capable of causing profound immunodeficiency and death.
Recent evidence suggests that many HIV-2 isolates are significantly less fit than group M HIV-1 isolates in terms of replicative and transmission capacity (7) . However, some HIV-2 isolates have been shown to replicate well in PBMC (7) (8) (9) and deplete CD4 ϩ T cells in ex vivo lymphoid tissue cultures (10) . The proviral burden of HIV-2 is similar to that of HIV-1 in individuals at equivalent stages of disease (11) (12) (13) . However, the plasma viral load is significantly lower in most HIV-2-infected individuals (14) . This presumably contributes to substantially lower rates of vertical and horizontal HIV-2 transmission (15, 16) . Collectively, these data suggest that a different dynamic equilibrium of host and virus is established during HIV-2 infection, raising the possibility that control of viral replication may in part be due to a more efficient host immune response to HIV-2 (17) .
Studies of the cellular immune response to HIV-2, though limited in number, have demonstrated vigorous HIV-2-specific cytotoxic T cell responses in HIV-2-infected subjects (18, 19) . In addition, more recent studies have shown that HIV-1-and HIV-2-specific CD8 ϩ T cells have similar capacity to produce IFN-␥ and proliferate (20, 21) , suggesting that enhanced viral control in HIV-2-infected people is not associated with these aspects of the virusspecific CD8
ϩ T cell response. Although some HIV-2-infected individuals have been shown to mount a CD4 ϩ T cell response (22) (23) (24) (25) , there have been no studies to date investigating multiple functional and phenotypic parameters of HIV-2-specific CD4 ϩ T cells.
In this study, we examined T cell immune responses to HIV-2 and HIV-1 in a well-characterized group of individuals attending a clinic in The Gambia, West Africa (Table I ). In a cross-sectional analysis of 39 HIV-1 ϩ and 33 HIV-2 ϩ donors stratified by CD4 ϩ T cell count, we quantified the HIV-specific CD4 ϩ T cell response by intracellular cytokine staining (ICS) for IFN-␥ and IL-2 and examined surface expression of CD57 for evidence of terminal differentiation. In addition, we monitored the proliferative capacity of HIV-specific CD4 ϩ and CD8 ϩ T cells. We show that nonprogression in HIV-2 infection is associated with strong HIV-2-specific CD4 ϩ T cell responses, particularly a non-terminally differentiated, polyfunctional population of cytokine-producing cells with preserved proliferative capacity.
Materials and Methods

Study population
This study was conducted at the Medical Research Council (MRC) Laboratories in Fajara, The Gambia, West Africa. A total of 72 HIV-infected individuals, 39 HIV-1 ϩ and 33 HIV-2 ϩ , was recruited from the clinical HIV cohort attending the Genitourinary Medicine Clinic based at the MRC Unit. Additionally, 21 confirmed HIV-seronegative blood donors were recruited from the National Blood Bank at the Royal Victoria Teaching Hospital in Banjul, The Gambia. As antiretroviral therapy (ART) was not available in The Gambia until recently, all study subjects in this study were untreated. All individuals recruited for this study were infected with either HIV-2 or HIV-1 and were seronegative for the other virus. Individuals with dual HIV-1 ϩ HIV-2 ϩ infection were excluded from the study. For analysis, study subjects were stratified into three categories based on CD4 ϩ T cell percentage rather than absolute CD4 count as this has proven to be a more reliable indicator of HIV-induced lymphopenia and mortality in the developing world (20, 26, 27) . These stratifications included individuals with a CD4 percentage (CD4%) within the normal range (CD4% Ն28), symptomatic individuals who had an intermediate CD4% (CD4% ϭ 14 -27), and those individuals with clinical AIDS with a CD4% Ͻ14%. Percentages of CD4 ϩ T lymphocytes were determined by flow cytometry using BD MultiTest reagents and MultiSet software (BD Immunocytometry Systems). Patients' characteristics are detailed in Table I . Study participants were screened for HIV-1 and HIV-2 using the Murex ICE HIV-1.2.0 capture enzyme immunoassay (Murex Diagnostics). All reactive samples were confirmed as HIV-1 or HIV-2 positive using two type-specific competitive ELISAs (Murex Diagnostics). HIV-1 and HIV-2 plasma viral loads were measured by an in-house reverse-transcriptase PCR assay using specific long terminal repeat primers (28) . The lower limit of detection for viral load assays was 100 RNA copies/ml. Samples with PCR signals below the level of detection were assigned a viral load value of 100 RNA copies/ml. HIV-1-infected individuals consistently had a greater mean plasma viral load than HIV-2-infected individuals at CD4 count Ͼ14%, however, HIV-2-infected individuals at highly advanced stages of disease had a higher mean plasma viral load than HIV-1-infected AIDS patients (Table I) . This is likely due to the small number of HIV-2-infected individuals with advanced disease and is likely inflated by two individuals with very high viral loads, Ͼ300,000 copies/ml. Additionally, HIV-2 viral load has been shown to increase during Plasmodium falciparum infection in parasitemic individuals (29) and concomitant malaria infection cannot be ruled out as a cause of high viral load in these HIV-2-infected individuals. Ethical approval was obtained from the Gambian Government/MRC Ethics Committee and each study participant gave informed consent before entry into the study.
Synthetic peptides
Twenty-mer peptides overlapping by 10 aa corresponding to Gag sequences (p17 and p24) of the HIV-2 subtype A consensus and HIV-1 clade A consensus strains were synthesized as free amino acids (HIV-2 (Affiniti); HIV-1 (NIBSC); Ͼ85% purity by HPLC). Previous studies have shown that the majority of HIV-1 infections in The Gambia are CRF-02, an A/G recombinant strain of which the gag gene is subtype A (30, 31) , and HIV-2 infections are with subtype A virus (32) . Lyophilized peptides were resuspended in DMSO (Sigma-Aldrich) at 50 mg/ml. The overlapping 20 mer were grouped into an HIV-1 Gag pool (33 peptides) and an HIV-2 Gag pool (37 peptides) such that the concentration of each peptide in the pool was 400 g/ml. Small aliquots of the Gag peptide pool mixtures were stored at Ϫ80°C and peptides were used at a final concentration of 2 g/ ml/peptide in all experiments.
Monoclonal Abs and flow cytometric analysis
FITC, CFSE, PE, PerCP, and allophycocyanin were used as the fluorophores for these experiments. Unconjugated anti-human CD28 and antihuman CD49d were used as costimulatory Abs. mAbs used for the ICS assay were anti-CD57 FITC, anti-IL-2 PE, anti-CD4 PerCP, and anti-IFN-␥ allophycocyanin (BD Pharmingen). CFSE (Molecular Probes), anti-CD8 PE, anti-CD3 PerCP, and anti-CD4 allophycocyanin (BD Biosciences) were used for characterization of T cell proliferative responses. Four-parameter flow cytometric analysis was performed using a FACSCalibur flow cytometer (BD Biosciences). The list-mode data files were analyzed using FlowJo (Tree Star).
ICS for production of IFN-␥ and IL-2 by HIV-specific CD4
ϩ T cells
Ten to 15 ml of peripheral blood was collected via venipuncture and PBMC were isolated using Ficoll-Hypaque (Pharmacia) density centrifugation. This assay was performed only on freshly isolated PBMC and stimulation was performed as previously described (33) . Briefly, PBMC were resuspended at 10 6 /ml in RPMI medium supplemented with 10% heatinactivated FCS and 1 g/ml anti-CD28 and anti-CD49d costimulatory Abs. Due to restrictions on the number of PBMCs recovered from the small volume of venipuncture, this study was restricted to the study of HIV Gag-specific responses as this protein has been shown to be highly immunodominant in both HIV-1-and HIV-2-infected individuals (25, 34, 35) . Synthetic overlapping Gag peptide pools (final concentration 2 g/ml/peptide) were used to stimulated HIV-specific responses. HIV-1 or HIV-2 Gag peptide pools were used according to the status of the individual. These viruses share 60% amino acid homology in the Gag region (36) . For each individual, a negative control containing only anti-CD28 and anti-CD49d was used to measure Ag-independent stimulation and a positive control staphylococcal enterotoxin B (SEB; final concentration 2 g/ml) was used to ensure that cells were responsive. The cultures were incubated for 1 h at 37°C in a 5% CO 2 incubator, followed by an additional 5 h in the presence of Brefeldin A (10 g/ml; Sigma-Aldrich). Stimulated cells were washed, fixed/permeabilized (FACSPerm2; BD Biosciences), and stained for surface markers and cytokines of interest. Cells were then washed and resuspended in 2% paraformaldehyde in PBS for flow cytometric analysis.
Responses are reported after background correction, using the anti-CD28/ 49d-negative control to define nonspecific responses. A threshold of 0.1% was used to define a positive HIV Gag-specific CD4 ϩ T cell response because no negative control sample showed nonspecific responses above this level and HIV Gag peptides did not induce this level of nonspecific cytokine production in seronegative donors.
CD4
ϩ and CD8 ϩ T cell CFSE proliferation assay
Briefly, freshly isolated PBMC or freshly thawed cryopreserved samples rested overnight were resuspended in PBS at a concentration of 1-2 ϫ 10 6 /ml. Cells were stained with CFSE (final concentration 0.25 M; Molecular Probes) for 7 min in a 37°C water bath. CFSE labeling was then quenched with 3 ml of FCS and cells were washed three times with RPMI supplemented with 10% FCS. CFSE-labeled PBMC were resuspended at a final concentration of 1-2 ϫ 10 6 /ml in RPMI supplemented with 10% human AB serum (Sigma-Aldrich) and 1 g/ml anti-CD28 and anti-CD49d costimulatory Abs for culture. PBMCs from each individual were then stimulated with overlapping Gag peptide pools (2 g/ml/peptide), SEB (2 g/ml), or anti-CD28 and anti-CD49d alone (1 g/ml each) and cultured at a concentration of 1-2 ϫ 10 6 PBMC in a volume of 1 ml in 48-well plates (Nunc) at 37°C for 5 days. PBMC were then collected and stained for surface markers of interest and fixed with 2% paraformaldehyde in PBS. CFSE-labeled cells were kept free from excessive light to avoid photobleaching and were analyzed by flow cytometry within 24 h of staining.
Percentages of total CD4
ϩ or CD8 ϩ T cells that divided in response to Gag peptide stimulation were calculated using the proliferation platform of FlowJo. Values for Ag-specific responses are reported as the percent divided after subtraction of background proliferation in the unstimulated samples.
Statistical analysis
Statistical tests were performed using two-tailed 2 analysis, Fisher's exact test, two-sided ANOVA, Mann-Whitney U test, and Spearman rank correlations using GraphPad Prism 4.0a software and GenStat. Values of p were corrected for multiple comparisons and differences were considered statistically significant when p Ͻ 0.05 after correction.
Results
More HIV-2-than HIV-1-infected subjects have detectable HIV Gag-specific CD4
ϩ T cells ICS was used to monitor production of IFN-␥ and IL-2 by Agspecific CD4 ϩ T cells. Although HIV Gag-specific CD4 ϩ T cell responses were observed in the majority of both HIV-1-and HIV-2-infected subjects, more HIV-2-infected (85%; 28 of 33) than HIV-1-infected individuals (64%; 25 of 39) had CD4 ϩ T cells producing IFN-␥ in response to their respective Gag peptide pools ( p ϭ 0.04; Table II ). The difference was more marked for IL-2-producing CD4 ϩ T cells, which were detected in 64% of HIV-2-infected compared with 36% of HIV-1-infected individuals ( p ϭ 0.01). Interestingly, among individuals with a relatively preserved CD4 ϩ T cell count (Ͼ28%) 94% (16 of 17) of HIV-2-infected individuals had detectable IFN-␥-producing CD4 ϩ T cells, and 53% (9 of 17) had detectable IL-2-producing CD4 ϩ T cells. In contrast, 64% (7 of 11) of asymptomatic HIV-1-infected individuals had detectable IFN-␥-producing CD4 ϩ T cells, while only 9% (1 of 11) had IL-2-producing CD4 ϩ T cells (Table II) .
HIV-2-infected donors have higher frequencies of HIV-specific CD4 ϩ T cells than HIV-1-infected donors
We quantified the frequency of CD4 ϩ T cells producing IFN-␥ only, IL-2 only, or both IFN-␥ and IL-2 in response to stimulation with overlapping Gag peptides using flow cytometry (representative flow cytometric plots are shown in Fig. 1a ). In donors with relatively preserved CD4 ϩ T cell counts (Ն28%), a greater proportion of total CD4 ϩ T cells from HIV-2-infected subjects produced IFN-␥ in response to Gag peptides than from HIV-1-infected subjects (median 0.315 vs 0.130%; p ϭ 0.014) (Fig. 1b) . Additionally, the frequency of IL-2-producing HIV-specific CD4 ϩ T cells was significantly greater in HIV-2-infected individuals with preserved CD4 ϩ T cell counts (median 0.068%) than in CD4-matched HIV-1-infected individuals (median 0.012%; p ϭ 0.0077) (Fig. 1c) . The differences in HIV-specific CD4 ϩ T cell responses between HIV-1-and HIV-2-infected subjects were less obvious in donors with intermediate CD4 ϩ T cell counts (CD4% ϭ 14 -27) and were absent in donors with CD4% Ͻ14 (Fig. 1, b and c) .
CD4
ϩ T cell responses to the superantigen SEB did not differ between any group of HIV-1-and HIV-2-infected individuals (data not shown) and control experiments in HIV-seronegative blood donors demonstrated that HIV Gag peptides induced Ͻ0.1% of total CD4 ϩ T cells to produce either IFN-␥ or IL-2. Overall, the frequency of cytokine-producing HIV-specific CD4 ϩ T cells was far greater in HIV-2 ϩ individuals with preserved CD4
ϩ T cell counts than in HIV-1 ϩ individuals with comparable CD4 ϩ T cell counts; individuals infected with HIV-2 had a 2.4-fold higher median frequency of IFN-␥-producing CD4 ϩ T cells, and a 5.7-fold higher median frequency of IL-2-producing CD4 ϩ T cells, when stimulated with their respective Gag peptide pools. These trends were the same when individuals were stratified by absolute CD4 count rather than by CD4%. Significantly greater frequencies of IFN-␥-or IL-2-producing HIV-specific CD4 ϩ T cells were found among HIV-2-infected individuals with an absolute CD4 count Ն500 cells/ml compared with CD4-matched HIV-1-infected individuals (data not shown). These findings indicate that asymptomatic HIV-2 ϩ individuals maintain a more substantial HIV-specific memory CD4 ϩ T cell response than HIV-1 ϩ subjects.
HIV-specific CD4 ϩ T cells producing both IFN-␥ and IL-2 are detected exclusively in HIV-2-infected individuals
HIV-specific CD4
ϩ T cells that produced both IFN-␥ and IL-2 in response to HIV Gag peptides were detected at a frequency of Ͼ0.1% in 36% (12 of 33) of HIV-2 ϩ subjects, predominantly among individuals with a normal CD4 ϩ T cell percentage (Fig. 1,  a and d) . This population of CD4 ϩ T cells made a substantial a Ag-specific responses above 0.1% of total CD4 ϩ T cells producing cytokine were considered a positive response. Statistical significance was determined using 2 analysis or Fisher's exact test (for tests with less than five individuals in a category) and signifcant differences are in bold type.
contribution (Fig. 2a) . In contrast, this dual cytokine-producing population of HIV-specific CD4 ϩ T cells was absent (Ͻ0.1%) from all 39 HIV-1-infected individuals we studied (Figs. 1, a and d, and 2b) . In our cohort of HIV-1-infected donors, HIV-1-specific CD4 ϩ T cells responded to Gag peptides by producing either IFN-␥ or IL-2, but not both.
Those HIV-2-infected individuals with strong CD4 ϩ T cell responses to HIV-2 Gag peptides had high frequencies of CD4 ϩ T cells in all three functional populations: IFN-␥ only, IL-2 only, and polyfunctional IFN-␥ ϩ IL-2 ϩ . There was a strong correlation between the frequency of CD4 ϩ T cells producing only IFN-␥ and those CD4
ϩ T cells producing IL-2 alone (R ϭ 0.43, p ϭ 0.01; data not shown). There was also a very strong correlation between the frequency of polyfunctional IFN-␥ ϩ IL-2 ϩ CD4 ϩ T cells and the frequency of IFN-␥ only (R ϭ 0.69, p Ͻ 0.0001) or IL-2 only producing CD4
ϩ T cells (R ϭ 0.47, p ϭ 0.005; data not shown). This suggests that the CD4 ϩ T cell response to HIV-2 is indeed functionally heterogeneous and individuals with strong responses tend to have a total CD4 ϩ T cell response to the virus that is a compilation of at least three functionally distinct cytokine-producing populations.
The increase in HIV-specific CD4 ϩ T cells in HIV-2 infection is due to the presence of CD4 ϩ T cells lacking CD57 expression
An important function of CD4 ϩ T cells is their ability to proliferate in response to cognate Ag stimulation. Surface expression of CD57 is associated with the inability to proliferate and indicates terminal differentiation (37) . To determine whether the higher frequency of HIV-specific CD4 ϩ T cells in HIV-2-infected individuals was among the terminally differentiated (CD57 ϩ ) or non-terminally differentiated (CD57 Ϫ ) fraction, we measured CD57 expression on the HIV-1-and HIV-2-specific cytokine-producing CD4 ϩ T cells. We found that the increase in HIV-specific cytokine-producing CD4 ϩ T cells in HIV-2 ϩ as compared with HIV-1 ϩ subjects with preserved CD4 ϩ T cell counts was predominantly within the CD57 Ϫ fraction ( p ϭ 0.01, Fig. 3b ). There was no difference in the frequency of CD57 ϩ HIV-specific, cytokine-producing CD4 ϩ T cells among HIV-1-or HIV-2 infected individuals at any stage of disease (Fig. 3a) . These data indicate that the increase in HIV-2-specific CD4 ϩ T cells is predominantly made up of CD57 Ϫ cells, which likely retain proliferative capacity.
Interestingly, HIV-2-specific CD4 ϩ T cells that expressed CD57 were skewed toward IFN-␥-producing populations, with a mean 77% of the Gag-responsive CD4 ϩ T cells producing IFN-␥ alone (Fig. 3c) . HIV-2-specific CD4 ϩ T cells lacking CD57 expression were more polyfunctional in nature, with a greater percentage of CD4 ϩ T cells producing IL-2 in response to Gag peptides (Fig. 3d) .
Superior proliferative capacity of HIV-2-specific CD4 ϩ T cells
Ag-specific CD4 ϩ T cell proliferation has been regarded as a major indicator of functional CD4 ϩ T cell help. We used the
IFN-␥ alone (bottom right quadrant), IL-2 alone (upper left quadrant), or both IFN-␥ and IL-2 (upper right quadrant) in response to stimulus. Scatter plots show the proportion of CD4 ϩ T cells producing IFN-␥ (b) IL-2 (c) or both IFN-␥ and IL-2 (d) in HIV-2 ( ), HIV-1 ( ), or HIV-negative (‚)
donors in response to pooled Gag peptides. Median value in each category is delineated with a horizontal bar and represents total Ag-specific responses above background. A dotted line at 0.1% response indicates the level above which responses are considered to be positive. Data were logtransformed for analysis and statistical significance was determined using ANOVA and adjusted for multiplicity using the Holm step-down method. CFSE-based lymphoproliferation assay to monitor CD4 ϩ and CD8 ϩ T cell proliferative capacity in response to HIV Gag peptides in HIV-1 ϩ and HIV-2 ϩ study participants. Fresh PBMC from 14 HIV-1-and 18 HIV-2-infected individuals were isolated from a venipuncture 5-10 mo after the original time point. For those individuals who were lost to follow-up, we used frozen PBMC samples where available (14 HIV-1 and 8 HIV-2 samples collected between 16 mo before and 8 mo after the original time point). We could not complete the study for 11 of 39 HIV-1-and 7 of 33 HIV-2-infected individuals from our original cohort for whom there were no frozen historical samples.
Fresh or frozen PBMC were stimulated with Gag peptides, SEB, or costimulatory Abs alone for 5 days and proliferative responses were measured in the CD3 ϩ CD4 ϩ and CD3 ϩ CD8 ϩ T cell subsets (representative flow plots are shown in Fig. 4a) . Stimulation of PBMC from HIV-2-infected individuals with normal CD4 ϩ T cell percentages (Ն28%) with HIV-2 Gag peptides induced the proliferation of a median 0.6% of total CD4 ϩ T cells over 5 days (range 0.0 -3.1%; Fig. 4b) . In striking contrast, we observed a profoundly attenuated proliferative response in CD4 ϩ T cells from HIV-1-infected individuals with comparable CD4 ϩ T cell percentages. In these subjects, a median 0.2% of total peripheral blood CD4 ϩ T cells expanded in response to HIV-1 Gag peptides over 5 days (range 0.02-0.40%; p ϭ 0.03). These differences were also apparent when subjects were stratified by absolute CD4 count (data not shown). Thus, the proliferative capacity of HIV-2-specific CD4 ϩ T cells among individuals with normal CD4 ϩ T cell counts was 3-fold greater than that of CD4-matched HIV-1-infected individuals. This difference was not observed in individuals with CD4 ϩ T cell percentage below the normal range (Ͻ28%) where proliferative responses in both HIV-1-and HIV-2-infected individuals were diminished.
No difference in the capacity of HIV-2-and HIV-1-specific CD8 ϩ T cells to proliferate
In contrast to the differences we observed in the proliferative capacity of HIV-specific CD4 ϩ T cells between HIV-1 ϩ and HIV-2 ϩ individuals, we found no differences in the ability of HIV Gag-specific CD8 ϩ T cells from HIV-1-and HIV-2-infected individuals to proliferate in response to type-specific HIV Gag peptides (Fig. 4c) . The median frequencies of responding CD8 ϩ T cells were similar among individuals with a normal CD4 ϩ percentage, with responses of 0.60% in HIV-2 ϩ subjects compared with 0.89% in HIV-1 ϩ donors ( p ϭ 0.34). The frequency of proliferating CD8 ϩ T cells decreased as CD4 counts declined in both HIV-1-and HIV-2-infected individuals, but the median frequencies still did not differ significantly (0.17 vs 0.09%; p ϭ 0.99).
The frequency of polyfunctional IFN-␥
ϩ IL-2 ϩ CD4 ϩ T
cells correlates with the proliferative capacity of HIV-2-specific CD4
ϩ and CD8 ϩ T cells
Previous studies have shown that HIV-1-infected individuals who fail to control viral load even in the presence of ART have HIVspecific CD4 ϩ T cells that predominantly produce IFN-␥, and have a greatly diminished proliferative capacity (38, 39) . In contrast, we find that HIV-2 ϩ individuals have an expanded frequency of polyfunctional IFN-␥ ϩ IL-2 ϩ CD4 ϩ T cells which correlated with the proliferative capacity of both HIV-2-specific CD4 ϩ (R ϭ 0.44, p ϭ 0.02) and CD8 ϩ (R ϭ 0.44, p ϭ 0.02) T cells (data not shown). We also found that although HIV-2-infected individuals with a high frequency of HIV-specific IFN-␥ ϩ IL-2 ϩ CD4 ϩ T cells tended to have low or undetectable plasma viral load, there was no correlation between these parameters (data not shown).
Discussion
Although HIV-2 can, in a minority of infected individuals, cause AIDS indistinguishable from that caused by HIV-1, many HIV-2-infected people behave as LTNPs. This provides a unique natural human model in which to investigate correlates of immune protection against HIV disease progression. One of the characteristic immune defects in HIV-1 infection is the early loss of HIV-specific CD4 ϩ T cells with proliferative capacity and the ability to secrete IL-2 (3, 40), which leaves an impaired CD4
ϩ Th cell response that is skewed toward a population that produces IFN-␥ only (33, 39) . Indeed, aside from a unique population of HIV-1-infected individuals who meet the definition of LTNPs and some patients treated with highly active ART, HIV-specific CD4 ϩ T cell ؉ T cells producing each cytokine were considered a positive response. Total IFN-␥ production is the combined black and striped segments. Total IL-2 production is the combination of the gray and striped segments. Vertical lines stratify patients based on CD4 ؉ T cell percentage and pie charts depict the mean proportion of the total HIVspecific response contributed by each cytokine population in each stratified category.
responses are conspicuously absent or impaired in HIV-1 infection, irrespective of viral load and CD4 ϩ T cell count (1, 38, 39) . In this study, we demonstrate that HIV-2-infected subjects, especially those with preserved CD4 ϩ T cell counts, are distinct from HIV-1-infected individuals in that they maintain a proliferationcompetent, nonterminally differentiated, multiple cytokine-expressing HIV-specific CD4 ϩ T cell response. These findings extend previous studies that demonstrated preserved virus-specific proliferative responses in a small number of HIV-2-infected individuals (23, 24) . Although a prior study has shown that the magnitude of the HIV Gag-specific IFN-␥ response by ex vivo ELISPOT was not significantly different in HIV-1-and HIV-2-infected donors (25), we found using ICS that the magnitude of CD4 ϩ T cells responding to HIV Gag peptides was much greater among HIV-2-infected individuals.
HIV-specific CD4 ϩ Th cell function is reported to be impaired from the earliest stages of HIV-1 infection (40) , in the absence of prompt treatment with ART (2), which may be explained by the preferential infection of HIV-1-specific CD4 ϩ T cells (41) . The devastating impact of primary SIV infection on the CD4
ϩ T cell population in gut-associated lymphoid tissue, which accounts for the bulk of the body's CD4 ϩ T cells, has recently been documented in animal models (42, 43) , and a similar phenomenon is likely to occur in human HIV-1 infection, in which gut-associated lymphoid tissue CD4 ϩ T cells are profoundly depleted even in primary HIV-1 infection (44, 45) . The preservation of virus-specific T cell help in many subjects with HIV-2 infection suggests that HIV-2 may not preferentially infect or deplete HIV-2-specific cells in these subjects. Further studies to investigate whether HIV-2-specific CD4 ϩ T cells resist viral infection and, if so, by what mechanism are clearly warranted.
The critical features of CD4 ϩ T cell help that contribute to protective immunity probably differ among viral infections, but recent studies in other chronic viral infections have shown that Ag load and persistence dictate the functional profile of CD4 ϩ T cell responses, and that protective and effective responses, typified by those seen in CMV and EBV infections, are characterized by the presence of CD4 ϩ T cells that produce both IFN-␥ and IL-2 (46).
In keeping with these observations, we find that maintenance of a normal CD4 ϩ T cell count in HIV-2 infection is associated with a population of polyfunctional IFN-␥ ϩ IL-2 ϩ HIV-specific CD4 ϩ T cells that was absent in all HIV-1-infected individuals in our cohort. This polyfunctional CD4
ϩ T cell population contributes substantially (17-18%) to the total HIV-2-specific CD4 ϩ T cell response and the magnitude of this population correlates with the ability of both HIV-2-specific CD4 ϩ and CD8 ϩ T cells to proliferate in vitro. In a cross-sectional study of this nature, it is not possible to determine whether preserved CD4 ϩ T cell counts in the presence of virus-specific IFN-␥ ϩ IL-2 ϩ CD4 ϩ T cells is a cause or effect of this population. However, because this polyfunctional subset is found only among HIV-2-infected individuals, and has been shown to be a hallmark of effective immunity in other viral infections, the presence of this subset may be a contributing factor in the attenuated clinical phenotype of HIV-2 infection. Though polyfunctional IFN-␥ ϩ IL-2 ϩ HIV-1-specific CD4 ϩ T cells have been documented in rare HIV-1 LTNP (47), we did not detect them in our HIV-1-infected population which was not enriched for LTNP and may have predominantly comprised donors with typical disease progression at an early stage of infection.
Terminally differentiated CD57 ϩ T cells are often IFN-␥-producing effector cells (48) that lack proliferative capacity and die upon secondary stimulation (37) . In mice, these IFN-␥-producing effector cells are not precursors of memory CD4 ϩ T cells, which instead make IL-2 and proliferate on secondary stimulation (49) . Consistent with this paradigm, we found that HIV-2-specific CD57 ϩ CD4 ϩ T cells generally lacked IL-2 production and instead predominantly made IFN-␥. However, the HIV-2-specific CD57 Ϫ
CD4
ϩ T cells were more polyfunctional, with 29% producing IFN-␥ and IL-2, and 20% producing only IL-2. We observed similar trends in the two HIV-1-infected individuals who had a substantial CD57
ϩ HIV-specific CD4 ϩ T cell response (data not shown). These data demonstrate that the difference in frequency of HIV-specific CD4 ϩ T cells between asymptomatic HIV-1-and HIV-2-infected donors is predominantly driven by the non-terminally differentiated subset, which more frequently express IL-2. ϩ T cells that produced cytokine (IFN-␥ ϩ , IL-2 ϩ , or IFN-␥ ϩ IL-2 ϩ ) in response to pooled Gag peptides and express (a) or lack (b) cell surface expression of CD57 in HIV-2 ( ) and HIV-1 (F) donors. Median value in each category is delineated with a horizontal line. Values of p were generated using twotailed Mann-Whitney U test. Bar graphs depict the proportion of the total HIV-2-specific CD57 These cells are functionally more consistent with memory than effector Th cells and should retain proliferative capacity.
Intriguingly, despite the increased functionality of HIV-2-specific CD4 ϩ T cells, we found that the maintenance of CD4 ϩ T cell help in HIV-2-infected individuals is not reflected in increased proliferative capacity of HIV-2-specific CD8 ϩ T cells. This is in keeping with other studies that have demonstrated similar antiviral activity, phenotype, and function of virus-specific CD8 ϩ T cells in HIV-1-and HIV-2-infected donors at similar stages of disease (20, 21) . One potential explanation for these findings is that HIV-2-specific CD4 ϩ T cells themselves may have direct effector functions that are protective and antiviral and may be contributing to control of HIV-2 viremia via this mechanism. Alternatively, other aspects of CD8 ϩ T cell functionality that require CD4 ϩ T cell help may be enhanced in HIV-2-infected individuals. Indeed, many recent studies, mostly in murine models, have investigated the requirement of CD8 ϩ T cells for CD4 ϩ T cell help, and have suggested that CD4 ϩ T cells are required at the time of primary infection to ensure the expansion and maintenance of memory CD8
ϩ T cells in a secondary response (50) . In the absence of CD4 ϩ T cell help, the secondary CD8 ϩ T cell response is both smaller (51) and functionally impaired (51, 52) : that impairment is manifested in both reduced proliferative capacity and effector potential (lytic activity and IFN-␥ secretion). Fewer studies have examined the role of CD4 ϩ T cell help in supporting the CD8 ϩ T cell response in persistent infection, but in the lymphocytic choriomeningitis virus model, the maintenance and function of memory CD8 ϩ T cells are impaired in the absence of CD4 ϩ T cell help (53) . Consistent with these observations, impairments in HIV-1-specific CD8 ϩ T cell phenotype and function have been noted and ascribed to the lack of appropriate CD4 ϩ T cell help (54 -56) . Although we only measured the proliferative capacity of HIV-2-specific CD8 ϩ T cells, we found this activity to be intact in HIV-2-infected subjects who have preserved HIV-2-specific CD4 ϩ T cell function. Other studies have failed to detect differences in the magnitude or cytokine secretion profile of HIV-specific CD8 ϩ T cells between HIV-1-and HIV-2-infected subjects (20, 21, 25) . Similarly, we did not detect significant differences in the proliferative capacity of HIV-specific CD8 ϩ T cells between HIV-1-and HIV-2-infected subjects, despite the marked discrepancy in the levels of CD4 ϩ T cell help and viral load between the two groups. Assuming that CD8 ϩ T cells are the major antiviral effector arm of the immune system, it becomes difficult to reconcile our results. However, it is certainly plausible that other aspects of CD8 ϩ T cell function than those we have measured are more effective in HIV-2 infection than in HIV-1 infection and are responsible for the differences in control of these two human pathogens. Additionally, preserved HIV-2-specific CD4 ϩ T cell help could support other host immune responses such as enhanced neutralizing Ab activity (57, 58) or improved activation of APCs.
Although our cohorts of HIV-1-and HIV-2-infected individuals were matched in terms of CD4 ϩ T cell counts (both percentages and absolute counts are similar at equivalent stages of disease), plasma viral load was Ͼ10-fold lower among asymptomatic HIV-2-infected individuals. Either as a cause or consequence of this lower viral burden, HIV-specific CD4 ϩ T cells retain a robust proliferative capacity and ability to secrete multiple cytokines. Our findings of preserved polyfunctional CD4 ϩ T cell help in HIV-2 infection should provide a foundation upon which to investigate those aspects of human CD8 ϩ T cell activity that are dependent on CD4 ϩ T cell help. Our data also provide support for vaccine strategies that are designed to elicit a strong and polyfunctional CD4 ϩ T cell response in addition to a CD8 ϩ T cell response to HIV.
